他莫昔芬用于抑制卵母细胞取出周期中雌激素敏感的肿瘤复发。这项荟萃分析旨在评估促性腺激素和他莫昔芬联合给药的控制性卵巢刺激 (COS)（COS 与他莫昔芬）的质量。检索了 2022 年 10 月 30 日的 PubMed、Embase 和 Cochrane 图书馆的文章。作者包括研究比较 COS 与他莫昔芬、COS 联合促性腺激素和来曲唑（COS 联合来曲唑）或仅促性腺激素（COS 联合促性腺激素）对乳腺癌患者生育力保存的效果。主要结果指标是 COS 质量、回收卵母细胞总数 (TOR)、成熟卵母细胞总数 (TMO) 和雌二醇峰值水平 (PEL)。 四项研究（348 名患者、两项随机对照试验和两项队列研究） ）被纳入我们的荟萃分析中。 COS 联合他莫昔芬和 COS 联合来曲唑的 TOR（95% CI，[-3.84，2.90]）和 TMO（95% CI，[-2.20，2.64]）无显着差异。 COS 联合他莫昔芬和 COS 仅联合促性腺激素之间的 TOR 也没有差异（95% CI，[-6.14，1.86]）。与他莫昔芬相比，使用来曲唑的 COS 期间 PEL 出现统计学显着下降（95% CI，[1414.4, 4953.7]）。使用他莫昔芬的 COS 与仅使用来曲唑或促性腺激素的 COS 之间的质量没有差异。© 2023 作者。约翰·威利出版的《生殖医学和生物学》

Tamoxifen is used for the suppression of estrogen-sensitive tumor recurrence in oocyte retrieval cycles. This meta-analysis aimed to evaluate the quality of controlled ovarian stimulation (COS) with co-administration of gonadotropins and tamoxifen (COS with tamoxifen).PubMed, Embase, and Cochrane Library were searched for articles on October 30, 2022. The authors included studies comparing COS with tamoxifen and COS with gonadotropins and letrozole (COS with letrozole) or gonadotropin only (COS with gonadotropin only) for fertility preservation in patients with breast cancer. The main outcome measures were the COS quality, total number of retrieved oocytes (TOR), total number of mature oocytes (TMO), and peak estradiol levels (PEL).Four studies (348 patients, two randomized controlled trials, and two cohort studies) were included in our meta-analysis. There was no significant difference in TOR (95% CI, [-3.84, 2.90]) and TMO (95% CI, [-2.20, 2.64]) between COS with tamoxifen and COS with letrozole. There was also no difference in TOR (95% CI, [-6.14, 1.86]) between COS with tamoxifen and COS with gonadotropin only. Statistically significant decrease was observed in PEL during COS with letrozole compared with tamoxifen (95% CI, [1414.4, 4953.7]).The quality did not differ between COS with tamoxifen and COS with letrozole or gonadotropin only.© 2023 The Authors. Reproductive Medicine and Biology published by John Wiley & Sons Australia, Ltd on behalf of Japan Society for Reproductive Medicine.